Low-dose bacille Calmette–Guérin for non-muscle-invasive bladder cancer: Results of a prospective studyFootnote

Peer review under responsibility of Arab Association of Urology.

References

• A.JemalR.SiegelJ.XuE.WardCancer statistics, 2010CA Cancer J Clin602010277300
   PubMed Web of Science ®Google Scholar
• M.GrassoBladder cancer: a major public health issueEur Urol Suppl72008510515
   Web of Science ®Google Scholar
• H.NourO.AbdelrazakM.WishahyS.ElkatibH.BottoProstate-sparing cystectomy: potential functional advantages and objective oncological risks; a case series and reviewArab J Urol92011107112
   PubMedGoogle Scholar
• M.BabjukTransurethral resection of non-muscle-invasive bladder cancerEur Urol Suppl82009542548
   Google Scholar
• Z.XiaoE.HanelA.MakR.B.MooreAntitumor efficacy of intravesical BCG, gemcitabine, interferon-α and interleukin-2 as mono- or combination-therapy for bladder cancer in an orthotopic tumor modelClin. Med. Insights: Oncol.52011315323
   PubMedGoogle Scholar
• A.MoralesD.EidingerA.W.BruceIntracavitary bacillus Calmette–Guerin in the treatment of superficial bladder tumorsJ Urol1161976180183
   PubMed Web of Science ®Google Scholar
• M.BabjukW.OosterlinckR.SylvesterE.KaasinenA.BohleJ.Palou-Redortaet alEAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 updateEur Urol5920119971008
   PubMed Web of Science ®Google Scholar
• H.W.HerrA.MoralesHistory of bacillus Calmette–Guerin and bladder cancer: an immunotherapy success storyJ Urol17920085356
   PubMed Web of Science ®Google Scholar
• J.W.DavisS.I.ShethM.J.DoviakP.F.SchellhammerSuperficial bladder carcinoma treated with bacillus Calmette–Guérin: progression-free and disease specific survival with minimum 10-year follow upJ Urol1672002494501
   PubMed Web of Science ®Google Scholar
• M.H.AliI.Y.IsmailA.EltobgyA.GobeishEvaluation of second-look transurethral resection in restaging of patients with non-muscle invasive bladder cancerJ Endourol24201020472050
   Web of Science ®Google Scholar
• B.W.Van RhijnT.H.Van der KwastD.M.KakiashviliN.E.FleshnerM.N.van der AaS.Alkhateebet alPathological stage review is indicated in primary pT1 bladder cancerBJU Int1062010206211
   PubMed Web of Science ®Google Scholar
• M.AydinZ.TandogduF.O.KurtulusE.AvciA.FazliogluM.CekA prospective evaluation of second transurethral resection in non-muscle invasive bladder tumorsJ BUON152010514517
   Web of Science ®Google Scholar
• R.T.DivrikA.F.SahinU.YildirimM.AltokF.ZorluImpact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trialEur Urol582010185190
   PubMed Web of Science ®Google Scholar
• S.ZhuY.TangK.LiZ.ShangN.JiangX.Nianet alOptimal schedule of bacillus Calmette–Guerin for non-muscle-invasive bladder cancer: a meta-analysis of comparative studiesBMC Cancer132013332
   PubMed Web of Science ®Google Scholar
• M.BabjukW.OosterlinckR.SylvesterE.KaasinenA.BöhleJ.Palou-RedortaEAU guidelines on non-muscle-invasive urothelial carcinoma of the bladderEur Urol542008303314
   PubMed Web of Science ®Google Scholar
• M.BrausiL.ColletteK.KurthA.P.van der MeijdenW.OosterlinckJ.A.Witjeset alVariability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studiesEur Urol412002523531
   PubMed Web of Science ®Google Scholar
• A.I.KamelA.G.El BazW.T.Abdel SalamM.E.RyadA.A.MahenaLow dose BCG regimen in T1 transitional cell carcinoma of the bladder: long term resultsJ Egypt Natl Canc Inst212009151155
   Google Scholar
• F.PaganoP.BassiC.MilaniA.MeneghiniD.MaruzziA.GarbeglioA low dose bacillus Calmette–Guerin regimen in superficial bladder cancer therapy: is it effective?J Urol14619913235
   PubMed Web of Science ®Google Scholar
• H.W.HerrG.DalbagniS.M.DonatBacillus Calmette–Guérin without maintenance therapy for high-risk non-muscle-invasive bladder cancerEur Urol6020113236
   PubMed Web of Science ®Google Scholar
• P.U.MalmströmH.WijkströmC.LundholmK.WesterC.BuschB.J.Norlén5-year follow-up of a randomized prospective study comparing mitomycin C and BCG in patients with superficial bladder carcinomaJ Urol161199911241127
   PubMed Web of Science ®Google Scholar
• M.C.HallS.S.ChangG.DalbagniR.S.PruthiJ.D.SeigneSkinnerGuideline for the management of nonmuscle invasive bladder cancer [stages Ta, T1 and Tis]: 2007 updateJ Urol178200723142330
   PubMed Web of Science ®Google Scholar
• J.E.MontieP.E.ClarkM.A.Eisenbergeret alNational Comprehensive Cancer NetworkBladder cancerJ Natl Compr Canc Netw72009839
   PubMed Web of Science ®Google Scholar
• A.OjeaJ.L.NogueiraE.SolsonaN.FloresM.F.GómezJ.R.Molinaet alA multicentre, randomized prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette–Guerin [27 mg] versus very low-dose bacillus Calmette–Guerin [13.5 mg] versus mitomycin CEur Urol52200713981406
   PubMed Web of Science ®Google Scholar
• A.Z.WeizerC.TallmanJ.S.MontgomeryLong-term outcomes of intravesical therapy for non-muscle invasive bladder cancerWorld J Urol2920115971
   Web of Science ®Google Scholar
• M.H.IsmailM.M.WishahiA.AzizE.El ShimyA.KamelM.OsmanComplications of BCG immunotherapy for superficial bladder cancer: clinical comparison between Pasteur and Danish BCGMed J Cairo Univ641996119122
   Google Scholar
• O.SarhanB.Ali el DeinH.I.IbrahimM.A.GhoneimComplications of intravesical BCG therapy in superficial bladder tumors: a single centre studyEgypt J Urol8Suppl.200134 (abst.)
   Google Scholar
• D.L.LammB.A.BlunemsteinJ.D.CrissmanJ.E.MontieJ.E.GottesmanB.A.Loweet alMaintenance BCG immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group StudyJ Urol163200011241129
   PubMed Web of Science ®Google Scholar
• D.MackJ.FrickFive-year results of a phase II study with low-dose bacille Calmette–Guerin therapy in high-risk superficial bladder cancerUrology451995958961
   PubMed Web of Science ®Google Scholar